Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia

Mónica Villa-Álvarez 1,2,3†, Christian Sordo-Bahamonde 1,2,3†, Seila Lorenzo-Herrero 1,2,3, Ana P. Gonzalez-Rodriguez 2,3,4, Angel R. Payer 2,3,4, Esther Gonzalez-Garcia 3,5, María C. Villa-Álvarez 6, Alejandro López-Soto 1,2,3* and Segundo Gonzalez 1,2,3*

1 Department of Functional Biology, University of Oviedo, Oviedo, Spain, 2 University Institute of Oncology (IUOPA), University of Oviedo, Oviedo, Spain, 3 Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain, 4 Department of Hematology, Hospital Universitario Central de Asturias, Oviedo, Spain, 5 Department of Hematology, Hospital de Cabueñas, Gijón, Spain, 6 Department of Emergency Medicine, Hospital Vital Álvarez Buylla, Mieres, Spain

One of the cardinal features of chronic lymphocytic leukemia (CLL) is its association with a profound immunosuppression. NK cell function is markedly impaired in CLL patients, who show a significant dysregulation of the expression of activating and inhibitory receptors. Here, we analyzed the role of the novel inhibitory receptor Ig-like transcript 2 (ILT2, also termed LIR-1, LILRB1) in the regulation of NK cells in CLL. Our results show that ILT2 expression was significantly decreased on leukemic cells and increased on NK cells of CLL patients, particularly in those with advanced disease and with bad prognostic features, such as those carrying chromosome del(11q). The immunomodulatory drug lenalidomide may regulate the expression of ILT2 and its ligands in CLL since it significantly increased the expression of ILT2 and partially reestablished the expression of its ligands on leukemic cells. Furthermore, lenalidomide significantly increased the activation and proliferation of NK cells, which was strongly enhanced by ILT2 blockade. Combining ILT2 blockade and lenalidomide activated NK cell cytotoxicity resulting in increased elimination of leukemic cells from CLL patients. Overall, we describe herein the role of an inhibitory receptor involved in the suppression of NK cell activity in CLL, which is restored by ILT2 blockade in combination with lenalidomide, suggesting that it may be an interesting therapeutic strategy to be explored in this disease.

Keywords: chronic lymphocytic leukemia, NK cells, ILT2, lenalidomide, IL-2, checkpoint

INTRODUCTION

Chronic lymphocytic leukemia (CLL) is a lymphoproliferative malignancy characterized by the accumulation of clonal mature B cells in lymphoid organs, bone marrow, and peripheral blood. CLL patients display significant clinical heterogeneity, ranging from patients with indolent disease to patients with advanced stage disease, which require chemotherapy treatment. This clinical heterogeneity is associated with a heterogeneous array of chromosomal, genetic, and molecular defects (1). Thus, patients harboring chromosome del(17p)
or del(11q) have been associated with a poor clinical outcome (2–4), but CLL patients with del(13q) have been associated with a more favorable prognosis (5, 6).

Natural Killer (NK) cells are innate immune cells that play a key role in the immunosurveillance of hematopoietic malignancies. In CLL, NK cells are increased at diagnosis and early stage disease (7, 8). However, NK cell function is markedly impaired in advanced patients showing a profound deficiency of cytotoxic molecules and activating receptors (9–11). Particularly, the over-expression on NK cells of inhibitory receptors and its ligands may contribute to disease pathogenesis and resistance to immunotherapy (12, 13). Interestingly, targeting these inhibitory checkpoints has achieved noteworthy benefit in cancer patients by restoring an effective antitumor response (14, 15).

ILT2 (also named CD85j, LILRB1, or LIR-1) is an inhibitory receptor expressed by T cells, B cells, NK cells, and other immune cells (16–18). ILT2 ligands are both classical (HLA-A, -B, and -C) and non-classical MHC class I molecules (19–21). Specifically, ILT2 binds to HLA-G with a three- to four-fold higher affinity than to classical MHC class I molecules (21). The interaction of ILT2 with its ligands impairs the function and effector activity of NK cells (17, 21). Further, ILT2 inhibits the polarization of NK cell lytic granules and the microtubule organizing center (MTOC) and the accumulation of filamentous actin (F-actin) at the area of contact inhibiting intracellular calcium mobilization and IFN-γ polarized production by NK cells (22).

Immunomodulatory drugs, such as lenalidomide, have changed the therapeutic landscape in CLL showing that targeting the immune system represents an efficient therapeutic strategy in this disease (23–27). Lenalidomide is unable to induce direct apoptosis of leukemic CLL cells (25), but it regulates critical pro-survival and angiogenic cytokines and promotes the activation of T cells (28, 29). Moreover, it also increases NK cell proliferation, which correlates with clinical response (29–31). Significantly, the proliferation and activation of NK cells in CLL is mediated, at least in part, by the production of IL-2 by CD4+ T cells (32). Lenalidomide also enhances NK cell-mediated natural and Antibody-Dependent-Cell-Mediated Cytotoxicity (ADCC) against leukemic cells of CLL patients (32–34).

We recently reported a crucial role of ILT2 in the impairment of T cell function in CLL (35). In the present work, we show that ILT2 is also involved in the suppression of NK cells in CLL and we report that the combination of ILT2 blockade with lenalidomide restores NK cell function favoring the elimination of leukemic cells.

**PATIENTS, MATERIALS, AND METHODS**

**Patients**

Sixty consecutive non-treated CLL patients from the Hospital Universitario Central de Asturias fulfilling the diagnostic criteria for CLL (Table 1), and 25 age-matched healthy donors (mean age 59.5 years) were studied. This study was approved by the Ethics Committee of our institution (Comité de Ética de la Investigación del Principado de Asturias, 19042016) and informed consent according to the Declaration of Helsinki was obtained from all patients and controls. Both clinical and immunological characteristics of patients were analyzed when patients were enrolled in this study. Clinical and laboratory evaluation at visit included history and physical examination, standard clinical laboratory evaluation, evaluation for ZAP-70 by flow cytometry (20% cut-off), characterization of CD38 expression by flow cytometry (30% cut-off); and standard metaphase karyotype. Karyotype was categorized as complex, single abnormality or diploid. FISH analysis for 17p deletion, 11q deletion, trisomy 12, and chromosome 13q deletion was also performed. A total of 200 cells in interphase were analyzed for each probe. Positive patient cases were those with 5% or more cells with the abnormality. IGHV mutation status was characterized by direct sequencing method, and patients were categorized as unmutated (IGHV 98% germline homology) or mutated (98% homology).

| TABLE 1 | Clinical characteristics of CLL patients. |
|-----------------|-----------------|
| Patients        | Age (years, mean) | 67.4 |
| SEX             | Male             | 31   |
|                 | Female           | 29   |
| BINET STAGE     |                  |
| A               | 44               |
| B               | 7                |
| C               | 9                |
| RAI STAGE       |                  |
| 0               | 27               |
| I               | 16               |
| II              | 6                |
| III-IV          | 11               |
| ECOG PERFORMANCE STATUS |          |
| 0               | 47               |
| 1               | 9                |
| 2               | 4                |
| METAPHASIS KARYOTYPE (n = 44) |          |
| Complex         | 6                |
| Single abnormality | 14            |
| Diploid         | 24               |
| IGHV MUTATION STATUS (n = 47) |          |
| Unmutated       | 13               |
| Mutated         | 31               |
| Discordant      | 3                |
| CD38 EXPRESSION (n = 54) |   |
| Positive (≥30%) | 10               |
| ZAP-70 (n = 38) |                  |
| Flow positive (≥20%) | 8             |
| Progressive disease | 34            |
| Stable disease  | 26               |

Frontiers in Immunology | www.frontiersin.org 2 December 2018 | Volume 9 | Article 2917
Antibodies and Materials

Recombinant human interleukin 2 (IL-2; Peprotech), lenalidomide (reconstituted in DMSO; Selleckchem), sCD40L (Peprotech), HP-F1 anti-ILT2/CD85j blocking antibody (36, 37) (IgG1) provided by Miguel López-Botet (Universitat Pompeu Fabra, Spain) and an irrelevant IgG1 antibody (provided by JR de los Toyos-González, Universidad de Oviedo, Spain) were used in this study.

Flow Cytometry

For analyzing the expression of ILT2 and its ligands in different lymphocyte subsets, $1 \times 10^6$ PBMCs obtained from CLL patients and healthy donors were incubated with the corresponding antibodies at room temperature for 20 min. Anti-CD3-FITC, anti-CD56-APC, and anti-CD19-APC antibodies (all from Immunostep), anti-CD3-PECy7 and anti-CD56-PECy7 antibodies (eBioscience), and appropriate isotype-matched controls were used to define the immune subsets. Anti-ILT2-PE (clone HP-F1, eBioscience), anti-HLA-F rabbit antibody (Abgent), anti-HLA-G-PE (clone 87G Biolegend), anti-HLA-E-PE (clone 3D12 Biolegend), and a pan-anti-HLA-I antibody (clone W6/32) were used to measure the expression of ILT2 and its ligands in NK cells and B cells. NK cells were defined as CD3$^-$CD56$^+$, and B cells as CD19$^+$. Cells were analyzed on a BD Biosciences FACS Canto II cytometer (Beckton Dickinson).

NK Cell Activation

Peripheral blood mononuclear cells (PBMCs) obtained from CLL patients were cultured in the presence of anti-ILT2 blocking antibody (HP-F1; 10 µg/mL) or irrelevant mouse IgG1, and
lenalidomide (1 µM) and IL-2 (50 U/ml) for 7 days. The expression of CD69, CD25, CD137, NKG2D, and DNAM-I on NK cells (defined as CD3<sup>-</sup>CD56<sup>+</sup>) was evaluated by flow cytometry analysis using specific antibodies; anti-CD69-FITC (Immunostep), anti-CD25-PE (Biolegend), anti-CD137-PE (Biolegend), anti-NKG2D-PE (Miltenyi), and anti-DNAM-I-PE (Biolegend).

**Cell Proliferation**

PBMCs obtained from CLL patients were labeled with 1 µM 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE; Sigma-Aldrich) and cultured in the presence or absence of the anti-ILT2 blocking antibody (HP-F1) and lenalidomide (1 µM) for 14 days. Fresh lenalidomide was added to cell culture every 72 h. Then, cells were stained with specific antibodies for NK cells and

**FIGURE 2** ILT2 expression on NK cells associates with bad prognostic features of CLL patients. Histograms show the comparison of NK cells (A) and ILT2<sup>+</sup> NK cells (B) percentages among CLL patients stratified by the Binet stage. Comparison of the percentage of ILT2<sup>+</sup> NK cells in CLL patients stratified by the presence of chromosome del(11q) (C), trisomy 12 (D), del(13q) (E), and del(17) (F). Horizontal bars represent the mean ± SEM. SEM, Standard Error of the Mean; Mann-Whitney U-test; *P < 0.05.
Villa-Álvarez et al. ILT2 and Lenalidomide in CLL

FIGURE 3 | Effect of lenalidomide on ILT2 expression on NK cells and B cells from healthy donors and patients with CLL. The expression of ILT2 on NK cells and B cells from healthy donors (A,B) and patients with CLL (C,D) was evaluated by flow cytometry in PBMCs obtained from 4 CLL patients and 6 controls after the treatment with different doses of lenalidomide (LND) (0.1, 1, and 10 µM) for 7 days. The figure shows the comparison of the MFI of ILT2 expression normalized to the DMSO condition ± SEM. SEM, Standard Error of the Mean; Wilcoxon Matched-Pairs Signed Ranks test; *P < 0.05, **P < 0.01.

leukemia cells; and CFSE staining of different cell populations was analyzed by flow cytometry as we previously reported (32).

Leukemia Depletion Assay and Apoptosis
PBMCs from CLL patients were cultured in the presence or absence of anti-ILT2 blocking antibody (HP-F1) and lenalidomide for 7 days. Then, samples were stained with anti-CD19-FITC; and PKH26 reference microbeads (Sigma) were added to the samples according to manufacturer’s instructions. Flow cytometry analysis was performed by displaying 5,000 microbeads for each tube. CD19+ B-cell populations were gated, and the absolute counts of B cells were determined. The B cell numbers obtained with the antibody-untreated samples were set as 100% cells (equal 0% cell depletion). PBMCs from 11 CLL patients were cultured in the presence of the anti-ILT2 blocking antibody (HP-F1) and lenalidomide for 7 days, and apoptosis was evaluated using the Annexin V Assay and by flow cytometry analysis.

NK Cell Cytotoxicity and Perforin Production by NK Cells
In order to determine NK cell cytotoxic capacity, a calcein-based assay was performed. Briefly, effector cells (PBMCs from 5 patients with CLL) were cultured in the presence of anti-ILT2 blocking antibody (10 µg/mL) or mouse IgG1 (10 µg/mL) and lenalidomide (1 µM) for 7 days. Afterwards, K562 leukemia cells (ATCC) were labeled with calcein-AM (Invitrogen) following the manufacturers’ protocol and used as target cells. Specifically, 2 × 10⁴ K562 cells were co-cultured with effector cells at an 10:1 (E:T) ratio for 4 h in a 96-well plates. Calcein release was measured on a Varioskan™ LUX multimode microplate reader.
Intracellular perforin expression was evaluated on NK cells from PBMCs obtained from patients with CLL upon treatment with lenalidomide (1 µM), ILT2-blocking antibody (10 µg/ml) or irrelevant mouse IgG1 for a week. Then, cells were washed and incubated with PMA (50 ng/ml), ionomycin (1 µM) and brefeldin A (1 µM) for 4 h. Afterwards, cells were stained with anti-CD3 and anti-CD56 antibodies and permeabilized using BD Cytofix/Cytoperm™ solution kit. Perforin intracellular staining was evaluated in NK cells (CD3− CD56+) using a PerCP/Cy5.5 conjugated anti-human perforin antibody (Biolegend) following manufacturer's recommendations by flow cytometry analysis.

Statistics
The relationship between continuous and categorical prognostic variables was evaluated by Mann–Whitney U-test, and Wilcoxon Matched-Pairs Signed Ranks test was used for intra-group comparisons.

RESULTS
ILT2 Expression on NK Cells Is Increased in Patients With CLL
The expression of ILT2 on NK cells was analyzed in 60 patients with CLL and 25 healthy controls by flow cytometry (Figure 1A). Compared with healthy controls, the level of ILT2 expression on NK cells (Mean Fluorescence Intensity (MFI): 389.2 ± 217.8 vs. 717.9 ± 517.8, P < 0.01; Figure 1B) and the percentage of ILT2+ NK cells (4.2 ± 6 vs. 8.6 ± 9.1, P < 0.01; Figure 1C) were significantly increased in CLL patients. Contrarily, and in agreement with our previous report (35), ILT2 expression was significantly decreased on leukemic cells (Figure 1D). Of note, ILT2 expression on B cells from healthy donors was not altered by the treatment with the B cell activator molecule sCD40L, suggesting that ILT2 expression on B cells is not modulated by the activation status (data not shown).

Clinical analysis show that the percentage of NK cells was significantly decreased in patients with advanced stage of Binet
Lenalidomide Modulates the Expression of ILT2 and its Ligands in CLL Patients

We next analyzed whether the immunomodulatory drug lenalidomide modulates the expression of ILT2. For this purpose, PBMCs from 4 patients with CLL and 6 healthy donors were incubated with increasing doses of lenalidomide (0.1 to 10 µM) for 7 days and the expression of ILT2 was evaluated on NK cells and B cells by flow cytometry. As shown in Figure 3, lenalidomide significantly decreased the expression of ILT2 on NK cells from CLL patients, with no marked effect observed in NK cells from healthy donors. Noteworthy, treatment with lenalidomide significantly enhanced ILT2 expression on the surface of both healthy and leukemic B cells, being this effect more potent in the latter.

We reported that ILT2 ligand expression is deeply dysregulated on leukemic cells from patients with CLL (35). Specifically, the expression of HLA-E, HLA-F and HLA-G is diminished, while classical HLA class I molecules are increased on leukemic cells (35). Thus, we next asked whether lenalidomide modulates ILT2 ligand expression in CLL. As shown in Figure 4, lenalidomide reduced the levels of classical MHC class I molecules (P < 0.01) and increased HLA-E expression (P < 0.05) on leukemic cells; however, no significant effect was observed on the expression of HLA-G and HLA-F. Similarly, IL-2 increased the expression of HLA-E in these patients (P < 0.01).

Overall, these data indicate that lenalidomide partially restores the normal expression of ILT2 and its ligands in CLL.

Effect of ILT2 Blockade and lenalidomide on CD69 Expression and Proliferation of NK Cells

We next analyzed whether the HP-F1 antibody, which blocks the interaction between ILT2 and its ligands (36, 37), may increase the activation of NK cells. We also analyzed whether lenalidomide or IL-2 may cooperate with ILT2 blockade in this effect. Thus, PBMCs from 8 CLL patients were cultured in the presence of lenalidomide or IL-2 and the anti-ILT2 blocking antibody for 7 days and the expression of the immune activation marker CD69 was analyzed on NK cells by flow cytometry. ILT2 blockade and its combination with lenalidomide significantly increased the expression of CD69 on NK cells from CLL patients (Figure 5A). IL-2 also showed a cooperative effect with ILT2 blockade on NK cell activation. No significant effect of lenalidomide or anti-ILT2 blockade was observed on other NK cell activation and phenotypic markers including CD25, CD137, NKG2D or DNAM-1 (Figure 1S). Conversely, ILT2 blocking antibody and lenalidomide showed little capacity of activating leukemic cells (Figure 5B).

The effect on NK cell proliferation was next analyzed. CFSE-stained PBMCs obtained from 11 CLL patients were treated with anti-ILT2 blocking antibody alone or in combination with lenalidomide for 14 days, and the effect on the proliferation of NK cells was determined by flow cytometry analysis (Figure 6A). Lenalidomide significantly increased the proliferation of NK cells.
(68-fold, $P < 0.001$) and this effect was strongly enhanced by ILT2 blockade (156-fold, $P < 0.001$; Figure 6B). As previously reported (32), lenalidomide increased in a lesser extent the proliferation of leukemic cells ($P < 0.05$), but this effect was not further enhanced by ILT2 blockade (Figure 6C).

**ILT2 Blockade and lenalidomide Promote the Elimination of Leukemic Cells**

Next, the effect of ILT2 blockade and lenalidomide on the elimination of leukemic cells was evaluated. Thus, PBMCs from 6 patients with CLL were treated with anti-ILT2 blocking antibody and lenalidomide and the counts of leukemic cells were evaluated by flow cytometry at different time points (3, 5, and 7 days). Both ILT2-blockade and lenalidomide significantly diminished the numbers of leukemic cells in all the time points studied (Figure 7A). The observed reduction of leukemic cells was associated with an increase of leukemic cell apoptosis (Figure 7B). We showed that lenalidomide increases NK cell cytotoxic activity in CLL secondary to the production of IL-2 by CD4 T cells (32). In line with this, lenalidomide and ILT2 blockade significantly increased the intracellular levels of perforin on NK cells (Figure 7C). Concordantly, combination of lenalidomide and ILT2 blockade synergistically stimulated NK cell killing activity against K562 cells, as evaluated by calcein-based cytotoxic assay (Figure 7D).

Overall, our findings show that ILT2 blockade and lenalidomide have a significant effect on the elimination of leukemic cells of CLL patients, which was associated with an increased NK cell cytotoxic activity.

**DISCUSSION**

One of the key features of CLL is its association with a profound immunosuppression affecting to nearly all cells of the immune system including NK cells (9–11, 38). A relevant mechanism that account for the progressive loss of immune function in cancer is the sustained signaling of multiple inhibitory receptors, commonly known as checkpoints, such as PD1 and CTLA-4, which down-regulate the antitumor immune response (14, 39). These molecules have achieved increasing interest since targeting them has obtained an unexpected success in the treatment of...
some types of cancer. Likewise, the search for new checkpoint molecules in cancer is of crucial interest.

NK cells are cytotoxic lymphocytes specialized in early defense against virus infection and cancer cell transformation, particularly against hematological malignancies and metastasis (40). NK cell function is regulated by a delicate balance between signals provided by activating and inhibitory surface receptors that recognize their ligands on transformed cells (41–43). Negative regulation of NK cell function is controlled by an array of inhibitory receptors including killer immunoglobulin-like receptors (KIRs), NKG2A/CD94, the leukocyte immunoglobulin-like receptors, and the commonly considered checkpoint receptors (PD-1, TIM-3, LAG-3, and TIGIT). Interestingly, the loss of NK cell function in cancer is frequently caused by sustained signaling of multiple inhibitory receptors, and targeting these inhibitory receptors may restore NK cell activity providing a great benefit for these patients (15).

ILT2 is an inhibitory receptor involved in negative signaling in NK cells and other immune cells (16–18, 22, 36). Despite the fact that ILT2 has a significant capability of inhibiting the immune response, its role in cancer has achieved less attention than other checkpoint proteins. Nevertheless, we have recently shown that ILT2 is highly dysregulated in leukemic cells and CD8 and CD4 T cells of CLL patients, particularly in those patients having bad prognostic features, and it plays a significant role in the immunosuppression observed in those patients (35). Interestingly, targeting ILT2 restores T cell activity and ameliorates the immunosuppression. NK cells also exhibit...
reduced effector function in CLL, showing exhaustion features and functional defects in this disease (9–11). Our study shows that ILT2 may be involved in this immunosuppressed observed in NK cells since it is overexpressed on NK cells of CLL patients, particularly in advanced patients and those showing bad prognostic features, and it is involved in the suppression of NK cell antitumor activity.

Lenalidomide (Revlimid; Celgene) is an immunomodulatory drug that is used as an antineoplastic agent in CLL and other hematological malignancies (30, 31, 44). In CLL, significant clinical responses, including molecular complete remissions in heavily pre-treated patients, have been observed (44). Lenalidomide does not induce direct apoptosis of leukemic CLL cells (25), but it regulates critical pro-survival cytokines and promotes the activation of T cells (28, 29). Moreover, it also increases NK cell proliferation, which correlates with clinical response (29–31), and augments NK cell-mediated cytotoxicity (33). We showed that lenalidomide induces the activation and proliferation of NK cells and enhances the natural cytotoxicity and ADCC activity of NK cells in CLL (32). We also showed that this effect in CLL is, at least in part, mediated by the production of IL-2 by CD4+ T cells of CLL patients (32). Thus, lenalidomide is an interesting drug to be combined with therapeutic monoclonal antibodies since it may increase the antibody-dependent cytotoxicity of NK cells and it may cooperate with checkpoint inhibitors in the induction of the antitumor immune response mediated by NK and T cells. Consequently, an intense clinical and experimental research has been carried out to analyze new therapeutic strategies combining immunomodulatory drugs and monoclonal antibodies.

In this context, we decided to analyze the potential combination of lenalidomide and anti-ILT2 blocking antibody in the induction of the activity of NK cells of CLL patients. Our experiments show a novel effect of lenalidomide in regulating the immune response in CLL through the restoration, at least in part, of the expression of ILT2 and its ligands in leukemic cells of CLL patients. Thus, we previously showed that the expression of non-classical MHC class I molecules, namely HLA-G, HLA-E, and HLA-F, is decreased on leukemic cells (32). Contrarily, the expression of classical MHC class I molecules is increased in those cells (35). Here, our experiments show that lenalidomide increased the expression on leukemic cells of ILT2 and the non-classical MHC class I molecule HLA-E; but it decreased the expression of the classical ones. Similarly, lenalidomide also modulated the expression of ILT2 on leukemic cells; but, little effect was observed on NK cells, which suggests that lenalidomide may be an interesting drug to be combined with ILT2 blockade in the promotion of NK cell activity. In agreement, lenalidomide increased the activity, proliferation, and cytotoxicity of NK cells, and its effect was significantly potentiated by ILT2 blockade. These effects were associated, at least in part, with the induction of the apoptosis and elimination of leukemic cells. Despite the fact that the effect of lenalidomide and ILT2 blockade on T cells warrants further investigation, our results highlight their therapeutic potential in CLL.

It is of special interest the fact that a higher dysregulation of ILT2 expression on NK cells was observed in patients carrying a del(11q) and trisomy 12, which have been associated with enhanced clonal aggressiveness and worse evolution (2–6). The minimal region of deletion on 11q22.3–23.1 observed in CLL patients often involves the Radixin (RDX) and Ataxia telangiectasia mutated (ATM) genes. We reported that this deletion was also associated with a greater dysregulation of ILT2 expression in CD4+ T cells and leukemic cells (35), which may suggest that those patients may have a greater immunosuppression, which could account for their poor clinical outcome. This also suggests that these patients, which showed poor response to chemotherapy treatment, may be more prone to response to new immunotherapy strategies. Nevertheless, additional specific studies in larger populations are needed in order to draw definite conclusions.

Overall, our results show that ILT2 signaling in NK cells is profoundly dysregulated in CLL and targeting ILT2 may be a potential therapeutic strategy to be explored in this disease. Furthermore, the effect of ILT2 blockade on NK cell activity may be potentiated by its combination with the immunomodulatory drug lenalidomide, which is currently being used in the treatment of this disease.

**AUTHOR CONTRIBUTIONS**

MV-Á collaborated in the design of the study, designed and performed the experiments, analyzed the data and collaborated with the manuscript edition. CS-B designed and performed the experiments and analyzed the data. SL-H performed experiments and analyzed the data. AG-R, AP, and EG-G diagnosed the patients, made the clinical evaluation and laboratory analyses of the patients, collected and analyzed the clinical data, and collaborated with the manuscript edition. MCV-Á participated in the analysis of patients and the data. AL-S participated in the experimental design and development of the study, and collaborated with the manuscript edition. SG designed the study, analyzed the data, and wrote and edited the manuscript.

**FUNDING**

This work was supported by the Spanish grant of Instituto de Salud Carlos III (PI16/01485) and FEDER European Union. SL-H holds a Severo Ochoa Grant (BP14-150). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**ACKNOWLEDGMENTS**

The authors would like to thank Miguel López-Botet for providing us the HPF1 antibody and Juan Ramón de los Toyos-González for providing the mouse IgG1 antibody.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2018.02917/full#supplementary-material
ILT2 and Lenalidomide in CLL

Chona R, Arcebes-Huerta A, Gonzalez-Rodriguez AP, Fernandez-Guizan A, Pinyol M, Villamor N, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukemia. Nature (2011) 475:101–5. doi: 10.1038/nature 10113

Greipp PT, Smole SA, Viswanatha DS, Frederick LS, Rabe KG, Sharma RG, et al. Patients with chronic lymphocytic leukemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis. Br J Haematol. (2013) 163:326–33. doi: 10.1111/bjh.12534

Guieze R, Robbe P, Cliftord R, de Guibert S, Pereira B, Timbs A, et al. Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. Blood (2015) 126:2110–7. doi: 10.1182/blood-2015-05-647578

Knittel G, Liedgends P, Reinhardt HC. Targeting ATM-deficient CLL through interference with DNA repair pathways. Front Genet. (2015) 6:207. doi: 10.3389/fgene.2015.00207

Chiorazzi N. Implications of new prognostic markers in chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program (2012) 2012:76–87. doi: 10.1182/asheducation-2012.1.76

Hernandez-Rivas JA, Gonzalez-Gason YML. Genetic heterogeneity in chronic lymphocytic leukemia: what can conventional cytogenetics add? Acta Haematol. (2017) 138:31–2. doi: 10.1159/000477997

Gonzalez-Rodriguez AP, Contesti J, Huerzo-Zapico L, Lopez-Soto A, Fernandez-Guizan A, Acbes-Huerta A, et al. Prognostic significance of CD8 and CD4+ T cells in chronic lymphocytic leukemia. Leukemia Lymphoma (2010) 51:1829–36. doi: 10.3109/10428194.2010.503820

Palmer S, Hanson CA, Zent CS, Porrata LF, Laplant B, Geyer SM, et al. Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukemia. Br J Haematol. (2008) 141:607–14. doi: 10.1111/j.1365-2141.2008.07070.x

Parry HM, Stevens T, Oldreive C, Zadran B, McSkeane T, Rudzek Z, et al. NK cell function is markedly impaired in patients with chronic lymphocytic leukemia but is preserved in patients with small lymphocytic lymphoma. Oncotarget (2016) 7:68513–26. doi: 10.18632/oncotarget.12097

Huerzo-Zapico L, Acbes-Huerta A, Gonzalez-Rodriguez AP, Contesti J, Garcia-Garcia E, Payer AR, et al. Expansion of NK cells and impairment of NK cell function is markedly impaired in patients with chronic lymphocytic leukemia. Blood (2014) 123:2489–99. doi: 10.1182/blood-2013-10-578286

Maffei R, Fiorcari S, Martellini S, Benatti S, Bulgarelli J, Rizzotto L, et al. Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide. Leukemia Lymphoma (2018) 59:423–33. doi: 10.1080/10428194.2017.1339872

Lee BN, Gao H, Cohen EN, Badoux X, Wierda WG, Estrov Z, et al. Treatment with lenalidomide modulates T cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer (2011) 117:3999–4008. doi: 10.1002/cncr.25983

Chanon-Khan AA, Chitta K, Erising N, Paulus A, Masood A, Sher T, et al. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol. (2011) 155:457–67. doi: 10.1111/j.1365-2141.2011.08882.x

Kater AP, Tonino SH, Egle A, Ramsay AG. How does lenalidomide target the chronic lymphocytic leukaemia microenvironment? Blood (2014) 124:2184–9. doi: 10.1182/blood-2014-05-578286

Maffei R, Fiorcari S, Martellini S, Benatti S, Bulgarélli J, Rizzotto L, et al. Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide. Leukemia Lymphoma (2018) 59:423–33. doi: 10.1080/10428194.2017.1339872

Kater AP, Tonino SH, Egle A, Ramsay AG. How does lenalidomide target the chronic lymphocytic leukaemia microenvironment? Blood (2014) 124:2184–9. doi: 10.1182/blood-2014-05-578286

Maffei R, Fiorcari S, Martellini S, Benatti S, Bulgarelli J, Rizzotto L, et al. Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide. Leukemia Lymphoma (2018) 59:423–33. doi: 10.1080/10428194.2017.1339872

Aue G, Nguyen N, Tuan X, Soto S, Hughes T, Vire B, et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica (2009) 94:1266–73. doi: 10.3324/haematol.2009.008385

Lee BN, Gao H, Cohen EN, Badoux X, Wierda WG, Estrov Z, et al. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer (2011) 117:3999–4008. doi: 10.1002/cncr.25983

Chanon-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. (2006) 24:5343–9. doi: 10.1200/JCO.2005.05.0401

Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. (2009) 2:36. doi: 10.1186/1756-8722-2-36
antitumor immune responses mediated by NK and CD4 T cells. *BioMed Res Int.* (2014) 2014:265840. doi: 10.1155/2014/265840

33. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, et al. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. *Clin Cancer Res.* (2008) 14:4650–7. doi: 10.1158/1078-0432.CCR-07-4405

34. Bartlett JB, Wu L, Adams M, Schafer P, Muller G, Stirling D. Lenalidomide and pomalidomide strongly enhance tumor cell killing in vitro during antibody-dependent cellular cytotoxicity (ADCC) mediated by trastuzumab, cetuximab and rituximab. *J Clin Oncol.* (2007) 25(18_supp):3023. doi: 10.1200/jco.2007.25.18_supp.3023

35. Villa-Álvarez M, Lorenzo-Herrero S, Gonzalez-Rodriguez AP, López-Soto A, Payer AR, Gonzalez-Garcia E, et al. Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia. *OncoImmunology* (2017) 2017:e1353856. doi: 10.1080/2162402X.2017.1353856

36. Saverino D, Fabbi M, Ghiotto F, Merlo A, Bruno S, Zanco D, et al. The CD85/LIR-1/ILT2 inhibitory receptor is expressed by all human T lymphocytes and down-regulates their functions. *J Immunol.* (2000) 165:3742–55. doi: 10.4049/jimmunol.165.7.3742

37. Godal R, Bachanova V, Gleason M, McCullar V, Yun GH, Cooley S, et al. Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade. *Biol Blood Marrow Transplant.* (2010) 16:612–21. doi: 10.1016/j.bbmt.2010.01.019

38. Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. *Blood* (2015) 126:573–81. doi: 10.1182/blood-2015-03-567388

39. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. *Cancer Cell* (2015) 27:450–61. doi: 10.1016/j.ccell.2015.03.001

40. Lopez-Soto A, Gonzalez S, Smyth MJ, Galluzzo L. Control of metastasis by NK cells. *Cancer Cell* (2017) 32:135–54. doi: 10.1016/j.ccell.2017.06.009

41. Cerwenka A, Lanier LL. Natural killer cell memory in infection, inflammation and cancer. *Nat Rev Immunol.* (2016) 16:112–23. doi: 10.1038/nri.2015.9

42. Iannello A, Thompson TW, Ardolino M, Marcus A, Raulet DH. Immunosurveillance and immunotherapy of tumors by innate immune cells. *Curr Opin Immunol.* (2016) 38:52–8. doi: 10.1016/j.coi.2015.11.001

43. Huergo-Zapico L, Acebes-Huerta A, Lopez-Soto A, Villa-Alvarez M, Gonzalez-Rodriguez AP, Gonzalez S. Molecular bases for the regulation of NKG2D ligands in cancer. *Front Immunol.* (2014) 5:106. doi: 10.3389/fimmu.2014.00106

Conflict of Interest Statement: SG is the principal investigator of a research project in myeloma that is funded by Celgene.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Villa-Álvarez, Sordo-Bahamonde, Lorenzo-Herrero, Gonzalez-Rodriguez, Payer, Gonzalez-Garcia, Villa-Álvarez, López-Soto and Gonzalez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.